Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Félez

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Sangre|January 1, 1984
[Therapeutic advances against thromboembolic disease: II. The use of tissue fibrinolysis activator as a thrombolytic agent]F Rueda, J Félez
Medicina Clinica|April 26, 1987
[Thrombotic thrombocytopenic purpura]E Grau, J Félez
Thrombosis and Haemostasis|October 6, 1998
The emerging impact of phage display technology in thrombosis and haemostasisB Arza, J Félez
Sangre|January 1, 1985
[Inhibitors of fibrinolysis with special reference to anti-t-PA (inhibitor of the tissue plasminogen activator)]J Félez, F Rueda
Archives of Internal Medicine|August 1, 1986
Erythromycin-oral anticoagulants interactionE Grau, J Fontcuberta, J Félez
Medicina Clinica|April 29, 2000
[Angiostatin and its antitumor activity]J Félez, M Jardí, B Arza
Medicina Clinica|February 18, 1984
[Spontaneous retroperitoneal hemorrhage and anticoagulation]X Estivill, J Fontcuberta, J Félez
Medicina Clinica|March 15, 1986
[Thrombopathy caused by beta-lactam antibiotics]E Grau, J Fontcuberta, J Félez Brugués
Sangre|January 1, 1981
[Therapeutic advances in thromboembolic disease. I. Dihydroergotamine + heparin]I de Diego, F Jané, J Félez
Medicina Clinica|May 10, 1986
[Study of the segregation pattern of the genes responsible for hemophilia A]V Nunes, M Baiget, X Estivill, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Sangre|January 1, 1984
[Therapeutic advances against thromboembolic disease: II. The use of tissue fibrinolysis activator as a thrombolytic agent]F Rueda, J Félez
Medicina Clinica|April 26, 1987
[Thrombotic thrombocytopenic purpura]E Grau, J Félez
Thrombosis and Haemostasis|October 6, 1998
The emerging impact of phage display technology in thrombosis and haemostasisB Arza, J Félez
Sangre|January 1, 1985
[Inhibitors of fibrinolysis with special reference to anti-t-PA (inhibitor of the tissue plasminogen activator)]J Félez, F Rueda
Archives of Internal Medicine|August 1, 1986
Erythromycin-oral anticoagulants interactionE Grau, J Fontcuberta, J Félez
Medicina Clinica|April 29, 2000
[Angiostatin and its antitumor activity]J Félez, M Jardí, B Arza
Medicina Clinica|February 18, 1984
[Spontaneous retroperitoneal hemorrhage and anticoagulation]X Estivill, J Fontcuberta, J Félez
Medicina Clinica|March 15, 1986
[Thrombopathy caused by beta-lactam antibiotics]E Grau, J Fontcuberta, J Félez Brugués
Sangre|January 1, 1981
[Therapeutic advances in thromboembolic disease. I. Dihydroergotamine + heparin]I de Diego, F Jané, J Félez
Medicina Clinica|May 10, 1986
[Study of the segregation pattern of the genes responsible for hemophilia A]V Nunes, M Baiget, X Estivill, et al.
Pageof 5